Because responses to posts are no longer read by very many people, I'm reposting an earlier response to fuzzy. It's self explaining.
Fuzzy, as I've pointed out many times, LT, Boyd, Midatech, Lind, Bioasis and others have used their lawyers very well over the last 2 or 3 years. I've posted enough stuff to make it hard to argue that Bioasis wasn't purposefully placed under duress, xB3 wasn't downplayed, EGF wasn't camouflage and that other things aren't true.
For instance, buried in the 460-page AGM information circular and other documents was the statement that Midatech/Biodexa would become a therapeutics company, and would no longer be a drug delivery company.
You and everybody else missed it!
So why were those guys buying Bioasis if Biodexa would no longer be a drug delivery company? What was the point? EGF, alone, is not worth much. That statement in the deal documentation was meant as legal disclosure to the world that Biodexa would not keep xB3. And Rathjen knew that. She was part of the drafting of the agreement.
If Biodexa wasn't going to keep xB3, what was the point of Rathjen and Saltarelli joining the Biodexa board of directors? The answer is almost certainly that Dr. Deborah Rathjen and Dr. Mario Saltarelli would be joining whatever company bought xB3, likely Armistice, The Chosen Corp. Would Rathjen and Saltarelli remain with Biodexa if Biodexa retained only a handful of lower value xB3 therapeutics but not the xB3 Platform? Maybe, but the big win would be with The Chosen Corp, the private company that would have owned xB3.
Why did the Midatech financing with Armistice provide Armistice with the means to acquire over 90% of Biodexa through the exercising of their prepaid warrants? I think it possible that Armistice would cancel those prepaid warrants in exchange for xB3, meaning that Armistice, in reality, may have “bought” xB3 for nothing more, even before the Bioasis deal agreement was signed.
These are the types of conflicts of interest that Evans & Evans warned us about in their assessment of the deal. If it wasn’t for the Midatech shareholders, LT and The Gang would have achieved their goals. The Midatech shareholders cared more about the situation than the apathetic Bioasis shareholders who didn’t even bother to look closely at the deal. You Bioasis shareholders may still have time to call a special meeting and start getting Bioasis straightened out.
There are so many more of these types of situations in the deal and I have already written about them.
So don’t play dumb on this, fuzzy. It’s been laid out.
And if you have other more plausible explanations or revelations, let’s hear them. But if you’re not going to put some work into it, don’t bother.
jd